WEXFORD,
Pa., May 8, 2024 /PRNewswire/ -- Coeptis
Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or
"Coeptis"), a biopharmaceutical company developing innovative cell
therapy platforms for cancer, autoimmune, and infectious diseases,
announced today that the Company has been selected for an oral
presentation of the abstract titled Developing A First-In-Class
Universal Allogeneic Snap-Car NK Cell Therapy at the
International Society for Cell & Gene Therapy 2024, being held
May 28th to June 1st in Vancouver, Canada.
The Company's SNAP-CAR platform technology has demonstrated its
potential as a "universal" CAR therapy with the potential to target
multiple antigens through combinatorial use of different adaptors,
thus potentially avoiding toxicities and relapse due to antigen
loss. In Q3 of 2023, Coeptis expanded its exclusive license
agreement with the University of
Pittsburgh for SNAP-CAR to include natural killer (NK)
cells.
The background and aim of the abstract revolve around chimeric
antigen receptor (CAR) expression by engineered NK cells and the
ability to improve their innate anti-tumor functions by
specifically activating NK cells in the presence of tumor antigen.
Backed by research performed in conjunction with the University of Pittsburgh and Deverra Therapeutics,
allogeneic CAR NK cells may be a safer, more clinically accessible,
and cost-effective cellular therapy than autologous CAR T-cells.
Based on the demonstrated successful use of a novel SNAP-CAR
technology in T-cells, the Company is developing a first-in-class
universal allogeneic SNAP-CAR NK cell. This product replaces the
antigen binding domain of a CAR with a SNAP tag enzyme that carries
out a self-labeling reaction to covalently attach any antibody
conjugated to a benzylguanine (BG) tag to create a functional
antigen-specific CAR.
"ISCT 2024 is a prestigious gathering renowned for fostering
groundbreaking ideas and innovation," said Dave Mehalick, President and CEO of Coeptis
Therapeutics. "Our presentation represents a significant and
meaningful path forward in advancing our mission to develop a
proprietary, allogeneic cell generation platform aimed at
universalizing the treatment of many debilitating diseases."
Details of the presentations are outlined below:
TITLE: DEVELOPING A FIRST-IN-CLASS UNIVERSAL ALLOGENEIC
SNAP-CAR NK CELL
PRESENTATION TYPE: Oral, Thursday,
May 30, 2024 at 8am
AUTHORS: Carrie Stoltzman,
Erika von Euw, Braxton Jamison (presenting author),
Emily Hsieh, Kevin Green, Lara
Ionescu Silverman, Dan
Yerace, Dave Mehalick,
Colleen Delaney
INSTITUTIONS: Deverra Therapeutics, Seattle, WA, United
States
Coeptis Therapeutics, Wexford, PA, United
States
The International Symposium on Cell and Gene Therapy
(ISCT) brings together leading researchers, clinicians and
industry experts in cell and gene therapy from around the world.
Serving as a nexus for collaboration, the conference promotes the
exchange of new scientific advances, technological advances and
clinical insights in the rapidly developing field of cell and gene
therapy. For more information: www.isctglobal.org/isct2024.
About Coeptis Therapeutics Holdings, Inc.
Coeptis
Therapeutics Holdings, Inc., together with its subsidiaries
including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals,
Inc., (collectively "Coeptis"), is a biopharmaceutical company
developing innovative cell therapy platforms for cancer,
autoimmune, and infectious diseases that have the potential to
disrupt conventional treatment paradigms and improve patient
outcomes. Coeptis' product portfolio and rights are highlighted by
assets licensed from Deverra Therapeutics, including an allogeneic
cellular immunotherapy platform and DVX201, a clinical-stage,
unmodified natural killer cell therapy technology. Additionally,
Coeptis is developing a universal, multi-antigen CAR T technology
licensed from the University of
Pittsburgh (SNAP-CAR), and the GEAR cell therapy and
companion diagnostic platforms, which Coeptis is developing with
VyGen-Bio and leading medical researchers at the Karolinska Institutet. Coeptis' business model is
designed around maximizing the value of its current product
portfolio and rights through in-license agreements, out-license
agreements and co-development relationships, as well as entering
into strategic partnerships to expand its product rights and
offerings, specifically those targeting cancer and infectious
diseases. The Company is headquartered in Wexford, PA. For more information on Coeptis
visit https://coeptistx.com/.
Cautionary Note Regarding Forward-Looking
Statements
This press release and statements of our
management made in connection therewith contain or may contain
"forward-looking statements" (as defined in Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended). Forward-looking
statements include statements concerning our plans, objectives,
goals, strategies, future events or performance, and underlying
assumptions, and other statements that are other than statements of
historical facts. When we use words such as "may," "will,"
"intend," "should," "believe," "expect," "anticipate," "project,"
"estimate" or similar expressions that do not relate solely to
historical matters, we are making forward-looking statements.
Forward-looking statements are not a guarantee of future
performance and involve significant risks and uncertainties that
may cause the actual results to differ materially and perhaps
substantially from our expectations discussed in the
forward-looking statements. Factors that may cause such differences
include but are not limited to: (1) the inability to maintain the
listing of the Company's securities on the Nasdaq Capital Market;
(2) the risk that the integration of the Deverra licensed assets
will disrupt current plans and operations of the Company; (3) the
inability to recognize the anticipated benefits of the
newly-licensed assets, which may be affected by, among other
things, competition, the ability of the Company to grow and manage
growth economically and hire and retain key employees; (4) the
risks that the Company's products in development or the
newly-licensed assets fail clinical trials or are not approved by
the U.S. Food and Drug Administration or other applicable
regulatory authorities; (5) costs related to integrating the
newly-licensed Deverra assets and pursuing the contemplated asset
development paths; (6) changes in applicable laws or regulations;
(7) the possibility that the Company may be adversely affected by
other economic, business, and/or competitive factors; and (8) the
impact of the global COVID-19 pandemic on any of the foregoing
risks and other risks and uncertainties identified in the Company's
filings with the Securities and Exchange Commission (the "SEC").
The foregoing list of factors is not exclusive. All forward-looking
statements are subject to significant uncertainties and risks
including, but not limited, to those risks contained or to be
contained in reports and other filings filed by the Company with
the SEC. For these reasons, among others, investors are cautioned
not to place undue reliance upon any forward-looking statements in
this press release. Additional factors are discussed in the
Company's filings made or to be made with the SEC, which are
available for review at www.sec.gov. We undertake no obligation to
publicly revise these forward-looking statements to reflect events
or circumstances that arise after the date hereof unless required
by applicable laws, regulations, or rules.
Contacts
Coeptis Therapeutics, Inc.
IR@coeptistx.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/coeptis-therapeutics-to-present-its-universal-allogeneic-snap-car-nk-cell-therapy-at-the-isct-2024-302139107.html
SOURCE Coeptis Therapeutics, Inc.